Showing 1 - 10 of 11
Objective: To quantify direct costs of medication and cost of illness (according to functional capacity) for patients with rheumatoid arthritis (RA) in Germany, allowing further use in a health economic evaluation of sequential therapy with disease-modifying antirheumatic drugs (DMARDs) in...
Persistent link: https://www.econbiz.de/10005590526
Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation, stroke, cardiac...
Persistent link: https://www.econbiz.de/10005590312
Objective: To use published data to compare the economic consequences of specific immunotherapy (SIT) lasting 3 years with those of continuous symptomatic treatment in patients with either pollen or mite allergy. Design and setting: The evaluation was conducted from the following 3 perspectives...
Persistent link: https://www.econbiz.de/10005404993
Objective: To estimate, from the hospital perspective in Germany, the cost effectiveness of the low-molecular-weight heparin (LMWH) subcutaneous enoxaparin sodium 40mg once daily (ENOX) relative to no pharmacological prophylaxis (NPP) and relative to subcutaneous unfractionated heparin (UFH)...
Persistent link: https://www.econbiz.de/10004990355
Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). Objective: To determine the additional cost per patient-year of chronic...
Persistent link: https://www.econbiz.de/10005590520
Objective: Data from the Acute Infarction Ramipril Efficacy (AIRE) study were used in a cost-effectiveness analysis to determine the incremental cost per life-year gained (LYG) when the ACE inhibitor ramipril was added to conventional treatment in patients with heart failure after acute...
Persistent link: https://www.econbiz.de/10005449120
Alcoholism places a considerable economic burden on society. The rate of relapse of previously weaned alcoholics has been shown to decrease following treatment with acamprosate. Therefore, this study investigated the cost effectiveness of acamprosate in the treatment of alcoholism in Germany...
Persistent link: https://www.econbiz.de/10005404846
<Emphasis Type="Bold">Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). <Emphasis Type="Bold">Objective: To determine the additional cost per patient-year of chronic...</emphasis></emphasis>
Persistent link: https://www.econbiz.de/10011001575
<Emphasis Type="Bold">Objective: Data from the Acute Infarction Ramipril Efficacy (AIRE) study were used in a cost-effectiveness analysis to determine the incremental cost per lifeyear gained (LYG) when the ACE inhibitor ramipril was added to conventional treatment in patients with heart failure after acute...</emphasis>
Persistent link: https://www.econbiz.de/10011001609
<Emphasis Type="Bold">Objective: To estimate, from the hospital perspective in Germany, the cost effectiveness of the low-molecular-weight heparin (LMWH) subcutaneous enoxaparin sodium 40mg once daily (ENOX) relative to no pharmacological prophylaxis (NPP) and relative to subcutaneous unfractionated heparin (UFH)...</emphasis>
Persistent link: https://www.econbiz.de/10011001767